By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – UK biopharmaceutical firm Xention said today it has extended its drug discovery agreement with Japanese firm Ono Pharmaceutical for an additional year.

The companies originally signed their two-year agreement in March 2009 and have been successful in identifying multiple compounds, which selectively modulate the function of target ion channels, Xention said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.